Dr. Dino Prato argues standard cancer treatment uses only about 24 markers, missing the tumor's complexity. High-dimensional profiling examines over 1,000 markers across DNA, RNA, and immune profiles to find specific therapeutic targets instead of generic treatment.
Let's talk about the standard of care and some of the problems with what I call one-size-fits-all cancer treatment. So you're using maybe a biopsy, a tumor marker, and imaging, which is giving you maybe 24 markers. And if you're lucky, you might get some DNA biomarkers that give you some targets. But this is often a one-size-fits-all model. The problem is two cancers of the same type are very different. They have heterogeneity. And when you look at what we look at, which is 1,000+ markers— DNA, RNA, transcriptomics, immune spatial profiling, and immune spatial biology— we start to see a big difference in the targets.
